Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial

Authors: Zhang, Yuanyuan ^{a, ⁎}, Laine, Aaron M. ^a, Iyengar, Puneeth ^a, Westover, Kenneth D. ^a, Dowell, Jonathan E. ^b, Hughes, Randall S. ^b, Christie, Alana ^c, Mickel, Townes ^a, Attia, Albert ^d, Villaruz, Liza ^e, Chen, Yuhchyau ^f, Spigel, David R. ^g, Socinski, Mark A. ^e, Timmerman, Robert D. ^a, Gerber, David E. ^b

Source: In International Journal of Radiation Oncology, Biology, Physics January 2025

Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study

Authors: Choueiri, Toni K ^{a, *}, Merchan, Jaime R ^b, Figlin, Robert ^c, McDermott, David F ^d, Arrowsmith, Edward ^e, Michaelson, M Dror ^f, Tykodi, Scott S ^g, Heath, Elisabeth I ^h, Spigel, David R ⁱ, D’Souza, Anishka ^j, Kassalow, Laurent ^k, Perini, Rodolfo F ^k, Vickery, Donna ^k, Bauer, Todd M ^l

Source: In The Lancet Oncology January 2025 26(1):64-73

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Authors: Owen, Dwight H., Singh, Navneet, Ismaila, Nofisat, Blanchard, Elizabeth, Celano, Paul, Florez, Narjust, Jain, Dharamvir, Leighl, Natasha B., Mamdani, Hirva, Masters, Gregory, Moffitt, Pamela R., Naidoo, Jarushka, Phillips, Tanyanika, Riely, Gregory J., Robinson, Andrew G., Schenk, Erin, Schneider, Bryan J., Sequist, Lecia, Spigel, David R., Jaiyesimi, Ishmael A.

Source: Journal of clinical oncology. 41(5):e10-e20

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100181430192.0x000001&indx=1&recIds=ETOCvdc_100181430192.0x000001

Does This Patient Have a Family History of Cancer? An Evidence-Based Analysis of the Accuracy of Family Cancer History

Authors: Murff, Harvey J, Spigel, David R, Syngal, Sapna

Source: Murff, Harvey J and Spigel, David R and Syngal, Sapna (2004) Does This Patient Have a Family History of Cancer? An Evidence-Based Analysis of the Accuracy of Family Cancer History. Journal of the American Medical Association (JAMA) , 292 (12). pp. 1480-1489.

Relation: http://jama.ama-assn.org/content/292/12/1480.long; http://health-equity.pitt.edu/447/

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

Authors: Ramalingam, Suresh S., Thara, Eddie, Awad, Mark M., Dowlati, Afshin, Haque, Basir, Stinchcombe, Thomas E., Dy, Grace K., Spigel, David R., Lu, Sharon, Iyer Singh, Nithya, Tang, Yongqiang, Teslenko, Iryna, Iannotti, Nicholas

Source: Cancer. 128(1):65-74

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100137168126.0x000001&indx=1&recIds=ETOCvdc_100137168126.0x000001

Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor

Authors: Hrinczenko, Borys, Iannotti, Nicholas, Goel, Sanjay, Spigel, David, Safran, Howard, Taylor, Matthew H, Bennouna, Jaafar, Wong, Deborah J, Kelly, Karen, Verschraegen, Claire, Bajars, Marcis, Manitz, Juliane, Ruisi, Mary, Gulley, James L

Source: Future oncology. 18(11):1333-1342

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100187521979.0x000001&indx=1&recIds=ETOCvdc_100187521979.0x000001

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Authors: Singh, Navneet, Temin, Sarah, Baker, Sherman, Blanchard, Elizabeth, Brahmer, Julie R., Celano, Paul, Duma, Narjust, Ellis, Peter M., Elkins, Ivy B., Haddad, Rami Y., Hesketh, Paul J., Jain, Dharamvir, Johnson, David H., Leighl, Natasha B., Mamdani, Hirva, Masters, Gregory, Moffitt, Pamela R., Phillips, Tanyanika, Riely, Gregory J., Robinson, Andrew G., Rosell, Rafael, Schiller, Joan H., Schneider, Bryan J., Spigel, David R., Jaiyesimi, Ishmael A.

Source: Journal of clinical oncology. 40(28):3310-3322

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100172813183.0x000001&indx=1&recIds=ETOCvdc_100172813183.0x000001

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Authors: Spigel, David R., Faivre-Finn, Corinne, Gray, Jhanelle E., Vicente, David, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F., Garassino, Marina C., Hui, Rina, Quantin, Xavier, Rimner, Andreas, Wu, Yi-Long, Özgüroğlu, Mustafa, Lee, Ki H., Kato, Terufumi, de Wit, Maike, Kurata, Takayasu, Reck, Martin, Cho, Byoung C., Senan, Suresh, Naidoo, Jarushka, Mann, Helen, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J.

Source: Journal of clinical oncology. 40(12):1301-1311

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152856679.0x000001&indx=1&recIds=ETOCvdc_100152856679.0x000001

RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer

Authors: Paz‐Ares, Luis, Spigel, David R., Chen, Yuanbin, Jove, Maria, Juan‐Vidal, Oscar, Rich, Patricia, Hayes, Theresa, Calderón, Vanesa Gutiérrez, Caro, Reyes Bernabe, Navarro, Alejandro, Dowlati, Afshin, Zhang, Bin, Moore, Yan, Yao, Xiaopan, Kokhreidze, Jaba, Ponce, Santiago, Bunn, Paul A.

Source: Cancer. 128(9):1801-1811

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100148376066.0x000001&indx=1&recIds=ETOCvdc_100148376066.0x000001

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer

Authors: Awad, Mark M., Govindan, Ramaswamy, Balogh, Kristen N., Spigel, David R., Garon, Edward B., Bushway, Meghan E., Poran, Asaf, Sheen, Joong Hyuk, Kohler, Victoria, Esaulova, Ekaterina, Srouji, John, Ramesh, Suchitra, Vyasamneni, Rohit, Karki, Binisha, Sciuto, Tracey E., Sethi, Himanshu, Dong, Jesse Z., Moles, Melissa A., Manson, Kelledy, Rooney, Michael S., Khondker, Zakaria S., DeMario, Mark, Gaynor, Richard B., Srinivasan, Lakshmi

Source: In Cancer Cell 12 September 2022 40(9):1010-1026

A real-world clinicogenomic study of androgen receptor mutations and co-mutations in prostate cancer: Clinical implications.

Authors: Sturgill, Emma G., Luckett, Daniel J., Agrawal, Tarun, Best, Jordan T., Williams, Rikki N., Bupathi, Manojkumar, Fleming, Mark T., Schnadig, Ian D., Subbiah, Vivek, Spigel, David R., Burris III, Howard A., McKenzie, Andrew Jacob, Garmezy, Benjamin

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p73-73, 288p

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors: Adavosertib Plus Durvalumab for Solid Tumors: A Phase I Study: M.R. Patel et al.

Authors: Patel, Manish R., Falchook, Gerald S., Wang, Judy S., Imedio, Esteban Rodrigo, Kumar, Sanjeev, Miah, Kowser, Mugundu, Ganesh M., Jones, Suzanne F., Spigel, David R., Hamilton, Erika P.

Source: Targeted Oncology; Jan2025, Vol. 20 Issue 1, p127-138, 12p

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Authors: Jassem, Jacek, de Marinis, Filippo, Giaccone, Giuseppe, Vergnenegre, Alain, Barrios, Carlos H., Morise, Masahiro, Felip, Enriqueta, Oprean, Cristina, Kim, Young-Chul, Andric, Zoran, Mocci, Simonetta, Enquist, Ida, Komatsubara, Kimberly, McCleland, Mark, Kuriki, Hiroshi, Villalobos, Monette, Phan, See, Spigel, David R., Herbst, Roy S.

Source: In Journal of Thoracic Oncology November 2021 16(11):1872-1882

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Authors: Javle, Milind ^*, Borad, Mitesh J, Azad, Nilofer S, Kurzrock, Razelle, Abou-Alfa, Ghassan K, George, Ben, Hainsworth, John, Meric-Bernstam, Funda, Swanton, Charles, Sweeney, Christopher J, Friedman, Claire F, Bose, Ron, Spigel, David R, Wang, Yong, Levy, Jonathan, Schulze, Katja, Cuchelkar, Vaikunth, Patel, Arisha, Burris, Howard

Source: In The Lancet Oncology September 2021 22(9):1290-1300

Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer

Authors: Cho, Byoung Chul, Yoh, Kiyotaka, Perets, Ruth, Nagrial, Adnan, Spigel, David R., Gutierrez, Martin, Kim, Dong-Wan, Kotasek, Dusan, Rasco, Drew, Niu, Jiaxin, Satouchi, Miyako, Ahn, Myung-Ju, Lee, Dae Ho, Maurice-Dror, Corinne, Siddiqi, Shabana, Ren, Yixin, Altura, Rachel A., Bar, Jair

Source: In Lung Cancer September 2021 159:162-170

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

Authors: Park, Keunchil, Özgüroğlu, Mustafa, Vansteenkiste, Johan, Spigel, David, Yang, James C.H., Ishii, Hidenobu, Garassino, Marina, de Marinis, Filippo, Szczesna, Aleksandra, Polychronis, Andreas, Uslu, Ruchan, Krzakowski, Maciej, Lee, Jong-Seok, Calabrò, Luana, Arén Frontera, Osvaldo, Xiong, Huiling, Bajars, Marcis, Ruisi, Mary, Barlesi, Fabrice

Source: In Journal of Thoracic Oncology August 2021 16(8):1369-1378

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

Authors: Park, Keunchil, Özgüroğlu, Mustafa, Vansteenkiste, Johan, Spigel, David, Yang, James C.-H., Bajars, Marcis, Ruisi, Mary, Manitz, Juliane, Barlesi, Fabrice ^*

Source: In Lung Cancer April 2021 154:92-98

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial

Authors: Spigel, David R., Jotte, Robert M., Aix, Santiago Ponce, Gressot, Laurent, Morgensztern, Daniel, McCleod, Michael, Socinski, Mark A., Daniel, Davey, Juan-Vidal, Oscar, Mileham, Kathryn F., West, Howard, Page, Ray, Reinmuth, Niels, Knoble, Jeanna, Chen, Tianlei, Bhore, Rafia, Wolfsteiner, Marianne, Ong, Teng Jin, Gridelli, Cesare, Thomas, Michael

Source: In Clinical Lung Cancer January 2021 22(1):6-15

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)

Authors: Faivre-Finn, Corinne ^*, Spigel, David R., Senan, Suresh, Langer, Corey, Perez, Bradford A., Özgüroğlu, Mustafa, Daniel, Davey, Villegas, Augusto, Vicente, David, Hui, Rina, Murakami, Shuji, Paz-Ares, Luis, Broadhurst, Helen, Wadsworth, Catherine, Dennis, Phillip A., Antonia, Scott J.

Source: In Lung Cancer January 2021 151:30-38

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

Authors: Garassino, Marina C, Paz-Ares, Luis, Hui, Rina, Faivre-Finn, Corinne, Spira, Alex, Planchard, David, Özgüroğlu, Mustafa, Daniel, Davey, Vicente, David, Murakami, Shuji, Langer, Corey, Senan, Suresh, Spigel, David, Rydén, Anna, Zhang, Yiduo, O'Brien, Cathy, Dennis, Phillip A, Antonia, Scott J

Source: Future oncology. 17(10):1165-1184

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100187453992.0x000001&indx=1&recIds=ETOCvdc_100187453992.0x000001